<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930692</url>
  </required_header>
  <id_info>
    <org_study_id>03/21</org_study_id>
    <nct_id>NCT04930692</nct_id>
  </id_info>
  <brief_title>A Prospective Single-center Cohort Study &quot;Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients&quot;</brief_title>
  <official_title>A Prospective Single-center Cohort Study &quot;Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main hypothesis of this study is that contrast-enhanced CT lymphography can be used for&#xD;
      preoperative visualization of sentinel lymph nodes in breast cancer patients. We assume that&#xD;
      CT lymphography is a high-sensitivity and high-specificity method for sentinel lymph nodes'&#xD;
      mapping in breast cancer patients. We also assume that positive predictive value and negative&#xD;
      predictive value for identification of presence or absence of metastases in sentinel lymph&#xD;
      nodes (SLN) will be high enough for preoperative diagnosis of SLN metastases in breast cancer&#xD;
      patients. This study will use CT lymphography with periareolar injection of iopamidol and&#xD;
      standard protocols of sentinel lymph nodes biopsy using intraoperative indocyanine green&#xD;
      (ICG) fluorescence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of contrast-enhanced CT lymphography</measure>
    <time_frame>8 months</time_frame>
    <description>First primary endpoint is to determine the sensitivity and specificity of contrast-enhanced CT lymphography for the preoperative detection of sentinel lymph nodes in breast cancer in comparison with the intraoperative fluorescence method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preoperative detection of sentinel lymph nodes metastases</measure>
    <time_frame>8 months</time_frame>
    <description>Second primary endpoint is to assess the capabilities of contrast-enhanced CT lymphography for detecting metastases in sentinel lymph nodes in breast cancer patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective criteria for metastatic lesions of sentinel lymph nodes</measure>
    <time_frame>8 months</time_frame>
    <description>Secondary endpoint is to identify objective criteria for metastatic lesions of sentinel lymph nodes (SLN), such as 1) the shape of the lymphatic duct; 2) the contrast enhancement of the SLN (full or heterogeneous); 3) the size of the SLN; 4) the form of the SLN; 5) the density of the SLN.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>Preoperative SLNs mapping provided by CT-lymphography method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel lymph nodes will be mapped by contrast-enhanced CT lymphography in breast cancer patients. A mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride will be used as a contrast agent provided by periaoreolar injection. No later than 10 days after the CT lymphography patients will receive surgical treatment with sentinel lymph node biopsy using the ICG-fluorescence method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast-enhanced CT lymphography with the periareolar injection of iopamidol</intervention_name>
    <description>Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.&#xD;
No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator.</description>
    <arm_group_label>Preoperative SLNs mapping provided by CT-lymphography method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years;&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Iodine allergy;&#xD;
&#xD;
          -  Presence of distant metastases of breast cancer;&#xD;
&#xD;
          -  Body mass index more than 40;&#xD;
&#xD;
          -  Chronic cardiovascular and cerebrovascular diseases in the stage of decompensation or&#xD;
             recent acute conditions (myocardial infarction, brain stroke, etc.)&#xD;
&#xD;
          -  Suspected pregnancy;&#xD;
&#xD;
          -  Severe hypothyroidism;&#xD;
&#xD;
          -  Bronchial asthma in the stage of decompensation;&#xD;
&#xD;
          -  Decompensated diabetes;&#xD;
&#xD;
          -  Kidney or hepatic failure.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruslan Ahmedov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Petersburg State University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valeria Konstantinova, MD</last_name>
    <phone>+79315352637</phone>
    <email>konstantinova.valery@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint-Petersburg State University Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+7(812)676-25-25</phone>
      <email>6762525@gosmed.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Ruslan Ahmedov</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Sentinel lymph nodes</keyword>
  <keyword>CT-Lymphography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

